title: Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.
abstract: Oleanolic acid has significant pharmacological activities, such as anti-tumor, regulating blood sugar level and liver protection, which are more effective compared with free aglyconeoleanolic acid. However, it is still unknown if oleanolic acid affects the proliferation of human bladder cancer. We utilized T24 cells to study the effect of oleanolic acid on the proliferation and apoptosis of human bladder cancer. In this study, we found that the anti-cancer effect of oleanolic acid significantly suppressed cell proliferation and increased apoptosis and caspase-3 activity of T24 cells. Furthermore, Akt, mTOR and S6K protein expression was greatly inhibited in T24 cells under oleanolic acid treatment. Meanwhile, ERK1/2 of phosphorylation protein expression was significantly promoted by oleanolic acid treatment. Taken together, we provided evidences that oleanolic acid was Akt/mTOR/S6K and ERK1/2 signaling-targeting anti-tumor agent. These findings represent new evidences that oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling, and oleanolic acid may be used to prevent human bladder cancer.
authors.affiliation: Department of Urology, Air Force General Hospital Beijing 100142, China.
authors.forename: Da-Wei
authors.initials: DW
authors.lastname: Mu
authors.affiliation: Department of Urology, Air Force General Hospital Beijing 100142, China.
authors.forename: He-Qing
authors.initials: HQ
authors.lastname: Guo
authors.affiliation: Department of Urology, Air Force General Hospital Beijing 100142, China.
authors.forename: Gao-Biao
authors.initials: GB
authors.lastname: Zhou
authors.affiliation: Department of Urology, Air Force General Hospital Beijing 100142, China.
authors.forename: Jian-Ye
authors.initials: JY
authors.lastname: Li
authors.affiliation: Department of Urology, Air Force General Hospital Beijing 100142, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Su
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D009828:Oleanolic Acid / Q000494:pharmacology*; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D019893:Ribosomal Protein S6 Kinases / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D009828:Oleanolic Acid; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D019893:Ribosomal Protein S6 Kinases; D058570:TOR Serine-Threonine Kinases; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; C505407:CASP3 protein, human; D053148:Caspase 3
keywords: Akt; ERK1/2; Oleanolic acid; S6K; bladder cancer; mTOR
references.citation: Pharm Biol. 2014 Jun;52(6):789-95
references.pmid: 24824325
references.citation: Free Radic Res. 2014 Jul;48(7):794-805
references.pmid: 24678962
references.citation: J Cereb Blood Flow Metab. 2015 Jul;35(7):1055-68
references.pmid: 25899298
references.citation: Mol Cell Biochem. 2015 Feb;400(1-2):1-7
references.pmid: 25472877
references.citation: Eur J Med Chem. 2015 Jan 7;89:480-9
references.pmid: 25462260
references.citation: Mol Neurodegener. 2014;9:28
references.pmid: 25108425
references.citation: Eur J Med Chem. 2014 Jun 10;80:175-83
references.pmid: 24780594
references.citation: Front Aging Neurosci. 2013 Nov 05;5:64
references.pmid: 24204343
references.citation: Oncol Rep. 2014 Aug;32(2):567-72
references.pmid: 24912497
references.citation: Int J Oncol. 2014 Jan;44(1):27-34
references.pmid: 24190483
references.citation: Drug Des Devel Ther. 2015;9:3017-30
references.pmid: 26109845
references.citation: Exp Neurol. 2008 Sep;213(1):93-100
references.pmid: 18625500
references.citation: Curr Alzheimer Res. 2013 Mar;10(3):261-9
references.pmid: 23036022
references.citation: Curr Alzheimer Res. 2015;12(4):335-49
references.pmid: 25817254
references.citation: J Alzheimers Dis. 2009;16(4):809-21
references.pmid: 19387114
references.citation: Eur J Pharmacol. 2012 Sep 15;691(1-3):61-8
references.pmid: 22824464
references.citation: J Nutr Biochem. 2014 Nov;25(11):1154-60
references.pmid: 25172632
references.citation: Int J Clin Exp Pathol. 2011 Apr;4(4):385-402
references.pmid: 21577325
references.citation: Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):145-55
references.pmid: 22913737
references.citation: Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):88-90
references.pmid: 19266703
references.citation: J Drug Target. 2013 Nov 13;:null
references.pmid: 24219340
references.citation: Consult Pharm. 2013 Jul;28(7):443-54
references.pmid: 23835462
references.citation: J Alzheimers Dis. 2004 Dec;6(6):623-32; discussion 673-81
references.pmid: 15665402
references.citation: Curr Aging Sci. 2013 Jul;6(2):142-9
references.pmid: 23030129
references.citation: BMC Neurol. 2015;15:57
references.pmid: 25924912